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Background: the HIV care in Ethiopia has reached 79% coverage. 
The timeliness of the care provided at the different levels in the 
course of the disease starting from knowing HIV positive status to 
ART initiation is not well known. This study intends to explore the 
timing of the care seeking, the care provision and associated 
factors.  
Methods: This is a longitudinal follow-up study at seven university 
hospitals. Patients enrolled in HIV care from September 2005 to 
December 2013 and aged ≥14 years were studied. Different times in 
the cascade of HIV care were examined including the duration 
from date HIV diagnosed to enrollment in HIV care, duration from 
enrollment to eligibility for ART and time from eligibility to 
initiation of ART. Ordinal logistic regression was used to 
investigate their determinants while the effect of these periods on 
survival of patients was determined using cox-proportional hazards 
regression.  
Results: 4159 clients were studied. Time to enrollment after HIV 
test decreased from 39 days in 2005 to 1 day after 2008. It took 
longer if baseline CD4 was higher, and eligibility for ART was 
assessed late. Young adults, lower baseline CD4, HIV 
diagnosis<2008, late enrollment, and early eligibility assessment 
were associated with early ART initiation. Male gender, advanced 
disease stage and lower baseline CD4 were consistent risk factors 
for mortality.  
Conclusion and recommendation: Time to enrollment and duration 
of ART eligibility assessment as well as ART initiation time after 
eligibility is improving. Further study is required to identify why 
mortality is slightly increasing after 2010. 
Key words: HIV, HIV testing, enrollment, eligibility, antiretroviral 
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Ethiopia is one of the countries which were hard 
hit by HIV. The prevalence was 6.4% in 2001 and 
4.4 in 2003 (1, 2). The current prevalence of 1.2% 
leaves the country with close to 741,478 people 
living with HIV (3). There are 439,301 people 
who have ever been started on ART. In terms of 
total numbers the country has reached ART 
coverage of 79% (4).   
Several factors contributed positively towards 
this rapid expansion of the services. The 
unprecedented level of financial support received 
through PEPFAR and Global Fund, availability of 
guidelines for public-health approach, and strong 
commitment from the Ministry of Health/Federal 
HIV/AIDS Prevention and Control Office together 
with local leadership and partners contributed to 
these remarkable achievements (4). 
The focus of many reports has been on the 
number starting treatment and retention. One of 
the major aims of the national anti-retroviral 
program is to ensure that HIV-positive individuals 
are diagnosed, rapidly linked to an organized 
program of chronic HIV care, and placed on 
antiretroviral therapy as soon as they become 
eligible (5). It has been proved that if HIV 
infection is detected early and prompt linkage and 
treatment initiated, mortality and health care 
expenditure declines. Late initial access to ART 
poses serious risks. For instance, in South Africa, 
delaying initiation of ART as briefly as 30 days 
was found to pose a high risk of death (6).  In 
numerous studies, earlier access to ART – as 
measured by CD4 cell count – after a patient’s 
CD4 cell count falls to near 200, has been shown 
to be related to a lower risk of mortality (7). 
Linkage to care can be problematic. While 
the design and organization of the care cascade 
varies greatly depending on the country, access to 
ART in most low- and middle-income countries is 
generally a multi-step process, in which there is 
substantial loss at each step. In studies in sub-
Saharan Africa, a median of 41% of patients were 
found to be lost prior to receiving CD4 staging 
results, a median of 54% of those receiving CD4 
counts are lost prior to being found eligible for 
ART, and a median of 32% of those found eligible 
for ART are lost prior to starting ART (8).  
Under the Ethiopian national ART program, in 
2005-2008, 61% of persons testing HIV-positive 
were reported to have been “immediately” linked 
to chronic HIV care (9). A detailed analysis of 
2,191 adult patients who were enrolled in chronic 
HIV care between January 2003 and December 
2008, more than half the patients were linked from 
HIV testing to chronic care within one day, and 
half of those placed on chronic care initiated ART 
within 16 days. Waiting times were longest for 
patients entering care prior to the start of the 
national program, and shortest for patients 
entering during in the period 2005 to 2006 (10). 
There are various risk factors for delayed 
enrollment in HIV care. Some of these include 
lack of awareness, mental illness, fear of stigma 
and stigma (11). Other factors were responsible 
for late ART initiation in a multilevel study in 
Cameroon including male gender, knowledge 
about the disease, presence of integrated PMTCT 
service, place of residence, being single, level of 
education and period of treatment (12, 13). Most 
studies define late presentation as having low 
baseline CD4 cell count or other clinical criteria 
like being in advanced WHO Stage at presentation 
However, additional data is lacking on the typical 
time course for linkage to care and placement on 
ART in Ethiopia irrespective of baseline clinical 
characteristics.  
This study aims to use the advanced clinical 
monitoring (ACM) cohorts to provide an 
exploratory analysis of the time course from HIV 
diagnosis, to enrollment in chronic care, to ART 
start. It also intends to look at the effect of the 




Study setting and design: This study uses the 
Advanced Clinical Monitoring (ACM) cohort 
from the seven university hospitals providing 
chronic HIV care. The full description of the 
study design, participant selection, data collection 
process and full description of the study cohort 
can be found in the methodology paper (14). In 
short, this was a prospective observational 
longitudinal study. Study subjects were enrolled 
randomly from those in HIV care in the selected 
health facilities. 
Study sample and period: All adults and 
adolescents more than 14 years of age and 
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enrolled in the study cohort were included in the 
current study. This includes clients enrolled in 
care between 2005 and 2013. 
Independent variables: Age, gender, baseline 
WHO stage, baseline CD4 cell count, disclosure 
status, and period of enrolment in to HIV care are 
the explanatory variables.  
The Operational definitions used 
 HIV test is a laboratory test based on sample 
of blood to identify the presence of Human 
Immunodeficiency Virus in the body of a 
person. Test kit used is based on the national 
algorithm used at the time of testing (15). 
 Enrollment into HIV care is the process of 
being register in a health facility providing 
chronic HIV care services for the purpose of 
receiving antiretroviral therapy (ART) 
services. This is provided in clinics specially 
availed for this purpose (16). 
 Eligibility for ART is determined by looking 
at a set of predefined criteria according to the 
treatment guideline at a given time. The cut-
off for eligibility of treatment with 
antiretroviral therapy (ART) has varied over 
time (16-18). The baseline CD4 cell count 
cut-off has risen from ≤200 (before 2008), 
201 to 350 for WHO Stage III patients (2008-
2010), ≤350 (2011-2014) and at the time of 
analysis, it was at ≤500. As for clinical ART 
initiation criteria it has shifted from starting 
only WHO stage IV clients to WHO stage 3 
patients at time of analysis.  
 ART initiation is the process of 
administering highly active antiretroviral 
therapy (HAART) to a patient eligible for 
treatment with ART. Adherence preparation 
is provided for a defined time according to 
patient needs (16).   
 Survival in HIV care is defined as being 
alive at time of last observation. For clients 
that were lost to follow-up, tracing was done 
by phone, or home visit. For this purpose 
adherence supporters were available at each 
clinic who routinely received data from data 
clerks keeping records of clients with missed 
appointment. Adherence supporters would 
trace clients accordingly and update records. 
Clients found to be taking medications at a 
different facility were censored as were those 
lost to follow-up cases during survival 
analysis (14). 
Main study and outcome variables: Time from 
HIV diagnosis to enrollment in chronic HIV care 
(T-1), time from enrollment in chronic HIV care 
to eligibility for starting ART (T-2) and time 
from eligibility for ART to treatment initiation 
(T-3) were the main study variables. Each time 
variable was used to study its effect on the next 
time variable and survival that is effect of T-1 on 
T-2, T-3, and survival; effect of T-2 on T-3, and 
survival; and effect of T-3 on survival as shown 













Figure 1: Different time periods in the cascade of ART provision from time HIV status is known to enrollment (T-
1), to eligibility (T-2), to ART initiation (T-3), and finally to survival.  
 
Data source: De-identified and de-linked 
electronic record was used as data source. The 
data set was maintained at each study site. Data 
clerks were trained and assigned for the sole 
purpose of maintaining this database. All 
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consistency and accuracy with the original 
paper based medical records. This was done by 
onsite external support through a central data 
manager as well as at country level. Regular 
telephone co nference was held to ensure 
compliance to data recording and database 
updating procedures.     
Analysis: Stata statistical software Version 12 
was used to do statistical analysis. There were  
missing data elements from the following 
variables: age (12%), and gender (2%). 
Multiple imputations (multivariate normal 
regression) was used to estimate the missing 
values which was then used for analysis. All 
other variables were used for predicting 
missing values. As for descriptive statistics, 
number and percentages are used to provide 
description for categorical variables while 
median is used for continuous variables like 
time. Association between variables was 
determined with ordinal logistic regression 
whenever outcome variable was ordinal in 
nature (T-1, T-2, and T-3). Effect of 
independent variables on survival was 
determined by Cox-proportional hazards 
regression analysis. Only those variables 
significant during bi-variable analysis were 
included in the final model. Clients who were 
lost to follow-up or transferred to another 
facility or stopped treatment were censored 
from follow-up. Lost to follow-up was defined 
as not appearing for appointment for more than 
one month. Clients that were lost to follow-up 
were identified and traced by adherence 
supporters as described earlier. The effect of 
the changing eligibility criteria was accounted 
for by the use of time period categorization 
(2005-2007, 2008-2010, and 2011-2013), 
which is similar to the changing eligibility 
criteria, in regression analysis for modeling 
determinants for T-1 and T-3. For modeling 
time to eligibility (T-2) and survival, the 
changing eligibility criteria was examined by 
taking this time period and reviewing outputs 
separately for each time period (2005-2007, 
2008-2010, and 2011-2013) since comparing 
one group to another is not possible because of 
slower progression to eligibility and possibility 
for higher survival as the CD4 cut-off 
increased. Site level variability was accounted 
for during cox-regression analysis by 
stratification using site ID (19). Alph-value was 




All 4,159 patients eligible for study that that 
fell in the period free ART was initiated (after 
2004) who were older than 14 years were in the 
adult and adolescent cohort were included. 
Baseline characteristics of the patients are 
displayed in Table – 1 below. Most patients 
(92%) were above 24 years of age. More than 
half (61%) were female and 32% of all patients 
fall in the category of baseline CD4 count 
which is less than 100. 83% of patients have 
disclosed their HIV status. 
 
 
Figure 2: Trend of duration of time from knowing HIV status to enrollment in chronic HIV care, T-1 
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Table 1: Baseline characteristics of study subjects 
 
Variable Category Number (%) 
Age 15-24 312 (7.48%) 
 >24 3855 (92.51%) 
Sex Female 2532 (60.76%) 
 Male 1635 (39.23%) 
Baseline WHO Stage I or II 1394 (33.45%) 
 III or IV 2773 (66.54%) 
Baseline CD4 cell count <100 1313 (31.50%) 
 100-349 2485 (59.63%) 
 >349 369 (8.85%) 
Disclosure No 700 (16.79%) 
 Yes 3467 (83.20%) 
Period HIV diagnosed 2005-2007 1853 (44.46%) 
 2008-2010 1678 (40.26%) 
 2011-2013 636 (15.26%) 
Time from HIV test to enrollment ≤1week 3112 (74.68%) 
 1week-1 month 677 (16.24%) 
 >1 month 378 (9.07%) 
Time from Enrollment to eligibility ≤1week 2316 (55.57%) 
 1week-1 month 571 (13.70%) 
 >1 month 1280 (30.71%) 
Time from Eligibility to ART initiation 0 days 858 (20.59%) 
 ≤1 week 734 (17.61%) 
 1 week-1 month 955 (22.91%) 
 1 month- 1 year 587 (14.08%) 
 >1 year 1033 (24.79%) 
Last Status Active 3247 (77.92%) 
 Dead 464 (11.13%) 
 Lost 120 (2.87%) 
 Transferred to other facility 113 (2.71%) 
 Other 223 (5.35%) 
   
Time form HIV test to Enrollment: In 2005, 
the median duration of T-1 was 39 days and 
progressively dropped to one starting 2008 as 
shown in figure 2. Overall, around 75% of 
clients were enrolled in the first week after 
knowing their HIV status (Table 1). Upon 
examining factors which affect the length of T-1 
(Table 2), it can be seen that among those who 
eventually started ART, early enrollment was 
more likely in the earlier years of chronic HIV 
care (before 2007). Relatively speaking, it took 
longer for those with higher baseline CD4 cell 
count (>349) to enroll in care.  
Time form Enrollment to Eligibility: As seen 
on figure 3 below, the median duration for T-2 
has a declining trend after 2008 and remains at 
or below 2 days after that. Around 64% of 
clients are found to be eligible within one week 
of enrollment (Table 1).  
 
Figure 3: Trends of time from enrollment to 
eligibility - T-2 
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Table 2: Determinants of time from knowing HIV status to enrollment in chronic HIV care in ACM sites, 
2005- 2013. 
 
Variable Category Unadjusted Adjusted 
  OR P>z 95% CI OR    P>z 95% CI 
Age 15-24 1         
 >24 1.17 0.26      0.89-1.54    
Sex Female 1     1     
 Male 1.07 0.15      0.93-1.24 1.12 0.11 0.97-1.30 
Stage I or II 1        
  III or IV 1.12 0.13      0.97-1.30 0.94 0.42 0.80-1.10 
CD4 <100 1     1     
 100-349 1.17 0.05      1.00-1.36 1.15 0.10      0.98-1.35 
 >349 1.87 0.00       1.46-2.39 1.77 0.00       1.37-2.27 
Disclosure No 1          
 Yes 1.08 0.40      0.90-1.31    
Period HIV diagnosed 2005-2007 1     1     
 2008-2010 0.44 0.00 0.38-0.51 0.44 0.00 0.38-0.52 
 2011-2013 0.32 0.00 0.25-0.41 0.31 0.00 0.25-0.40 
 




As seen on Table 3 below, it can be seen that 
relatively speaking, asymptomatic patients and 
those with lower baseline CD4 cell count) were 
assessed to be eligible early on. It took longer 
time for those with higher CD4 cell count at 
baseline to become eligible and this was true 
across all time periods. In the period 2008-2010, 
late eligibility assessment was additionally 
associated with non-disclosure and female 
gender.  
Time from Eligibility to ART initiation: As 
seen on Figure 4 below, T-3 has been increasing 
over the years. 48% of client started treatment 
within one month of eligibility for ART (Table 
1). Upon examining the factors it took longer for 
younger adults, asymptomatic patients, those 
Variable Category Period HIV diagnosed 
  2005-2007 2008-2010 2011-2013 
  Adj.    
OR 
P>z Adj.    
OR 
P>z Adj.    Odds Ratio P>z 
Age 15-24 1  1  1  
 >24 1.30 0.14 0.85 0.41 0.77 0.48 
Sex Female 1  1  1  
 Male 0.83 0.06 0.70 0.00 0.88 0.50 
Stage I or II 1  1  1  
  III or IV 0.47 0.00 0.61 0.00 0.80 0.23 
CD4 <100 1  1  1  
 100-349 1.89 0.00 2.62 0.00 1.58 0.02 
 >349 2.84 0.00 3.25 0.00 1.68 0.11 
Disclosure No 1  1  1  
 Yes 0.79 0.07 0.74 0.02 1.29 0.26 
Time from test to enrolment ≤1week 1  1  1  
 1week-1 month 1.47 0.00 1.69 0.00 1.83 0.02 
 >1 month 1.44 0.01 3.52 0.00 0.70 0.55 
       Exploratory Analysis of Time from ART…                                                      Alula MT. et al. 
 
DOI: http://dx.doi.org/10.4314/ejhs.v27i1.3S  
 
23 
with higher CD4 (≥100), those diagnosed with 
HIV after 2007, those who were enrolled within 
one week of HIV diagnosis and those who 
became eligible 1 month after enrollment to 
initiate ART after eligibility (Table 4). 
 




Figure 4: Trends in time from eligibility for ART to initiation of treatment-T-3 
 
Treatment outcome: The majority (78%) of 
clients was still active in care at the end of 
follow-up while 11% died and 3% were lost to 
follow-up (Table 1). 
Mortality: As can be seen in Table 5 below, 
male gender, advanced disease stage and very 
low baseline CD4 cell counts (<100) were risk 
factors for mortality across the different 
Variable Category Unadjusted Adjusted 
  OR P>z 95% CI OR    P>z 95% CI 
Age 15-24 1     1     
 >24 0.75 0.01 0.61-.91 0.77 0.01 0.63-0.95 
Sex Female 1        
 Male 1.03 0.57 0.92-.15    
Stage I or II 1     1     
  III or IV 0.67 0.00 0.60-.76 0.92 0.16 0.81-1.04 
CD4 <100 1     1     
 100-349 1.40 0.00 1.24-.58 1.15 0.02 1.02-1.31 
 >349 1.43 0.00 1.15-.77 1.12 0.28 0.90-1.41 
Disclosure No 1     1     
 Yes 0.87 0.06 0.75-.00 0.90 1.83 0.78-1.05 
Period HIV diagnosed 2005-2007 1     1     
 2008-2010 1.23 0.00 1.09-.39 1.36 0.00 1.20-1.55 
 2011-2013 1.70 0.00 1.45-.99 1.92 0.00 1.62-2.26 
Time from test to enrolment ≤1week 1     1     
 1week-1 month 0.77 0.00 0.65-.90 0.80 0.01 0.68-0.94 
 >1 month 1.03 0.78 0.85-.24 0.79 0.03 0.65-0.97 
Time from enrolment to eligibility ≤1week 1     1     
 1week-1 month 0.81 0.00 0.68-.95 0.80 0.01 0.68-0.95 
 >1 month 8.06 0.00 6.83-.51 8.48 0.00 7.15-10.07 
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treatment periods. Even though direct 
comparison is not possible among the different 
time periods, mortality was found to be higher 
among those diagnosed with HIV after 2010. 
Early enrollment, eligibility assessment 
(mostly), and initiation of treatment later after 
eligibility were found not to be risk factor for 
mortality. Neither did age, and disclosure status.  
 





Figure 5: Kaplan Meier Survival Estimates on Time to Death by HIV Diagnosis Year 
Variable Category Period enrolled in HIV care 
  2005-2007 2008-2010 2011-2013 
  Adj.    
Haz. 
Ratio 
P>z Adj.     
Haz. 
Ratio 
P>z Adj.     Haz. Ratio P>z 
Sex Female 1  1  1  
 Male 1.53 0.01 1.61 0.00 1.10 0.70 
Stage I or II 1  1  1  
  III or IV 2.07 0.00 1.81 0.00 2.06 0.01 
CD4 <100 1  1  1  
 100-349 0.39 0.00 0.46 0.00 0.52 0.02 
 >349 0.57 0.01 0.32 0.01 0.68 0.40 
Time from Eligibility to ART initiation 0 days 1  1  1  
 ≤1 week 0.90 0.60 0.85 0.53 0.85 0.67 
 1 week-1 month 0.68 0.08 0.79 0.33 0.49 0.07 
 >1 month 0.92 0.67 0.74 0.24 0.44 0.04 
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All in all, the different milestones in the 
continuum of HIV care provision were being met 
in relatively better time intervals. Time to 
enrollment (T-1), and time to eligibility (T-2) were 
within one week for nearly 75% and 64% of 
clients, while ART initiation was within one 
month following eligibility in 48% of cases. The 
percentage of clients active in care was 77% in the 
study cohort, while those who died amounted to 
11%. 
The pattern of late enrollment of clients 
earlier in the roll out of the national free 
antiretroviral treatment program (2005-2007) 
could be attributed to service delivery factors like 
weak referral and linkage at the time where the 
program was still in its infancy. This has greatly 
improved later on as peer supporters or educators 
started providing linkage and counseling support. 
In Ethiopia this was started in 2007. (20-23) 
Another factor potentially attributable for this may 
be the technical assistance provided by 
international non-governmental university partners 
through PEPFAR (US President's Emergency Plan 
for AIDS Relief) program. (24) Late enrollment 
could also be due to patient factors as evidenced 
by longer time for linkage after diagnosis among 
those with higher CD4 cell count (25, 26). This 
may be because healthier patients didn’t feel the 
need for immediate follow-up as it happens with 
many chronic illnesses (27). On the other hand, 
earlier enrollment for those with lower CD4 cell 
count may point to a very acceptable health 
seeking behavior since these are the clients who 
needed care sooner than later. However, this must 
be seen separately form the more common case 
where those with lower CD4 or advanced WHO 
stage fail to link to care at all for several reasons 
including accessibility of health facilities. (28)  
The fact that the majority of clients become 
eligible in the first week of enrollment indicates 
that first, the assessment to determine eligibility 
was being carried out effectively in most of the 
study facilities; second, most clients enrolling in 
care becoming eligible indicates the late 
appearance of most clients for treatment after 
progressing to advanced disease stages. (29-31) 
The fact that more healthy patients (asymptomatic 
and those with higher baseline CD4 cell count) 
became eligible as time went by may be a 
reflection of the fact that eligibility criteria 
changed from lower (<200) to higher (<350) CD4 
cut-off. (32) It is no surprise that clients with 
higher baseline CD4 cell count took longer time to 
become eligible which is in line with slow CD4 
progression for those who present to care soon 
after infection or with higher CD4 cell count. (18, 
33) 
A significant proportion of clients started 
ART soon after eligibility (48%); that is, within 
one week. This is rather a worrisome pattern since 
it is important to take time to prepare clients for 
treatment well before commencing ART. National 
as well as international guideline clearly state that 
at least 2 to 3 visits be taken for adherence 
counseling and preparation and start other 
important preventive therapies like cotrimoxazol 
preventive therapy. (5, 18, 34) The potential 
negative effect to this may be reflected in poor 
treatment adherence, increased risk for side effects 
or even mortality especially whenever there are 
hidden opportunistic infections like tuberculosis. 
(35-37) Increased risk for mortality has also been 
documented in this study among those starting 
ART sooner as compared to those starting ART 
after one week from eligibility experiencing much 
better survival. This was statistically significant 
after 2011 with better long term survival for those 
starting ART one month after eligibility. 
Therefore, from this point of view, it is good news 
that the median ART initiation time is 
progressively increasing and approaching the two 
weeks limit as shown in figure 4. However, long 
term mortality was modeled to be better if early 
ART was not associated with lost to follow-up or 
mortality in a study done in sub-Saharan Africa. 
(38) In the current study, late initiation after 
eligibility was associated with younger age, 
diagnosis after 2007 and late eligibility assessment 
(>1 month) and higher baseline CD4 count. 
Accessibility is not an issue in this scenario since 
most of the clients were residents near study sites 
or within the town the health facility in question. It 
may be the result of late CD4 cell count 
assessment or at times negligence by providers to 
implement improved eligibility criteria. That may 
be the reason behind most of these cases being 
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recorded in the period where these adjustments 
tool place.  
Other important factors associated with 
mortality include being male gender, having low 
baseline CD4, and advanced disease stage at ART 
initiation. These factors were reported in several 
studies as well that consistently show that late 
presentation is associated with adverse outcomes. 
(39) 
This study shades light in the progress the 
HIV care in the study sites took from the earlier 
periods to the very recent past. It also identifies 
key challenges that may require further 
investigation as the program evolves. For instance, 
with the current cut off for eligibility being at an 
ever higher level of 500 CD4 cell counts, people 
may become even more reluctant to start treatment 
because of the general wellbeing they experience 
or late enrollment. (4) This may hamper efforts to 
initiate other interventions like positive living, 
tuberculosis prophylaxis, and so on. Therefore, as 
further criteria are introduced that promote 
initiation of treatment for more healthier people, 
the role of peer educators or adherence supporters 
and health care providers may become even more 
important to stress the advantage of starting 
treatment sooner than later. Another curious 
finding is that while disclosure of HIV status was 
high at 83% as reported in other studies as well, it 
was not associated with timely enrollment, ART 
initiation, or better survival even though it is 
known that clients who have disclosed have better 
adherence to medication. (40, 41) At the same 
time, the study has identified lingering 
implementation challenges resulting in late 
enrollment, late eligibility assessment and late 
ART initiation which require further follow-u. 
Finally, further study is required as to why 
mortality is higher among those diagnosed with 
HIV after 2011 which is paradoxical since 
eligibility has progressively increased and patients 
are starting care earlier. 
Limitations 
The primary limitation of this study is that it 
includes only those patients who reached the point 
of ART treatment. Therefore, it is subject to 
survival bias. (19, 42) The distribution of time 
courses from diagnosis to treatment may not be 
representative of the overall HIV+ population for 
a number of reasons. The ACM cohort has a bias 
toward identifying those patients with better 
access to care, earlier. It does not include HIV+ 
patients who were diagnosed but never access 
clinical care or those who died or were lost to 
follow up before they started ART having started 
follow-up.  
The other limitation is data quality. There 
were missing data elements for which statistically 
estimation was done through imputation. Even 
though this represents probably the best scientific 
guess, some outcomes may still have been 
affected. Another issue is the level of lost to 
follow-up. At 3%, even though, it is much lower 
than previous reports from other studies (10, 43), 
it still possess a challenge to make definitive 
conclusion concerning mortality estimates and 
determinants. 
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